Investigating survival, quality of life and cognition in PROton versus photon therapy for


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
20 03 2023
Historique:
entrez: 20 3 2023
pubmed: 21 3 2023
medline: 23 3 2023
Statut: epublish

Résumé

The use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from radiation. This is principally beneficial and holds promise of reduced long-term side effects. However, the sparing of seemingly non-cancerous tissue is not necessarily positive for isocitrate dehydrogenase ( PRO-GLIO (PROton versus photon therapy in To implement proton therapy as part of standard of care for patients with ClinicalTrials.gov Registry (NCT05190172).

Identifiants

pubmed: 36940951
pii: bmjopen-2022-070071
doi: 10.1136/bmjopen-2022-070071
pmc: PMC10030923
doi:

Substances chimiques

Protons 0

Banques de données

ClinicalTrials.gov
['NCT05190172']

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e070071

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
Pediatr Blood Cancer. 2021 Sep;68(9):e29125
pubmed: 34114294
J Neurooncol. 2017 Jun;133(2):237-246
pubmed: 28540668
Clin Neurol Neurosurg. 2018 Nov;174:233-238
pubmed: 30292166
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
J Neurooncol. 2021 May;152(3):583-590
pubmed: 33751335
Semin Radiat Oncol. 2018 Apr;28(2):97-107
pubmed: 29735196
Radiother Oncol. 2019 Aug;137:95-101
pubmed: 31082632
Acta Oncol. 2011 Feb;50(2):212-22
pubmed: 21231783
J Neurooncol. 2015 Jan;121(2):365-72
pubmed: 25344884
Eur J Cancer. 1998 Nov;34(12):1902-9
pubmed: 10023313
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
Qual Life Res. 2013 Sep;22(7):1717-27
pubmed: 23184421
Qual Life Res. 1996 Feb;5(1):139-50
pubmed: 8901377
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Nat Rev Clin Oncol. 2017 Aug;14(8):483-495
pubmed: 28290489
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Front Oncol. 2018 Nov 28;8:440
pubmed: 30547008
BMC Health Serv Res. 2018 Jun 28;18(1):506
pubmed: 29954382
J Neurol. 2008 Nov;255(11):1770-6
pubmed: 18854912
Lancet Oncol. 2011 Jun;12(6):583-93
pubmed: 21474379
J Neurooncol. 2012 Jun;108(2):291-308
pubmed: 22354791
Sci Rep. 2021 Aug 19;11(1):16849
pubmed: 34413349
Eur J Cancer. 2013 Nov;49(16):3477-85
pubmed: 23896377
Pract Radiat Oncol. 2019 Jul - Aug;9(4):e356-e361
pubmed: 30790717
Eur J Cancer. 2020 Sep;137:10-17
pubmed: 32721633
Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101
pubmed: 24782454
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Lancet Oncol. 2021 Jun;22(6):813-823
pubmed: 34000245
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Arch Phys Med Rehabil. 1996 Feb;77(2):177-82
pubmed: 8607743
Acta Neuropathol. 2015 Apr;129(4):585-96
pubmed: 25701198
JAMA. 2012 Nov 14;308(18):1881-8
pubmed: 23099483
J Psychosom Res. 1993;37(2):147-53
pubmed: 8463991
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Neuro Oncol. 2017 May 1;19(5):625-635
pubmed: 28453751
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237
Cancer. 2015 May 15;121(10):1712-9
pubmed: 25585890

Auteurs

Liv Cathrine Heggebø (LC)

Department of Oncology, Oslo University Hospital, Oslo, Norway licahe@ous-hf.no.
Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Ida Maria Henriksen Borgen (IMH)

Department of Oncology, Oslo University Hospital, Oslo, Norway.
Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway.

Hillevi Rylander (H)

Skandion Clinic, Uppsala, Sweden.

Cecilie Kiserud (C)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Tonje Haug Nordenmark (TH)

Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway.
Department of Psychology, Faculty of Social Sciences, University of Oslo, Oslo, Norway.

Taran Paulsen Hellebust (TP)

Department of Medical Physics, Oslo University Hospital, Oslo, Norway.
Department of Physics, University of Oslo, Oslo, Norway.

Morten Egeberg Evensen (ME)

Department of Oncology, Oslo University Hospital, Oslo, Norway.
Section of Oncology, Drammen Hospital, Drammen, Norway.

Magnus Gustavsson (M)

Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Medical Radiation Science, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden.

Christina Ramberg (C)

Department of Medical Physics, Oslo University Hospital, Oslo, Norway.

Mette Sprauten (M)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Henriette Magelssen (H)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Hanne Blakstad (H)

Department of Oncology, Oslo University Hospital, Oslo, Norway.
Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Janani Moorthy (J)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Karin Andersson (K)

Skandion Clinic, Uppsala, Sweden.

Ingela Raunert (I)

Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.

Thomas Henry (T)

Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Medical Radiation Science, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden.

Cecilie Moe (C)

Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway.

Carin Granlund (C)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Dorota Goplen (D)

Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.

Jorunn Brekke (J)

Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.

Tor-Christian Aase Johannessen (TA)

Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.

Tora Skeidsvoll Solheim (TS)

Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Kirsten Marienhagen (K)

Department of Oncology, University Hospital of North Norway, Tromso, Norway.

Øyvind Humberset (Ø)

Department of Oncology, University Hospital of North Norway, Tromso, Norway.

Per Bergström (P)

Department of Oncology, University Hospital of Umeå, Umeå, Sweden.

Måns Agrup (M)

Department of Oncology, Linköping University Hospital, Linköping, Sweden.
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Ludvig Dahl (L)

Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.

Michael Gubanski (M)

Department of Radiotherapy, Karolinska University Hospital, Stockholm, Sweden.

Helene Gojon (H)

Department of Radiotherapy, Karolinska University Hospital, Stockholm, Sweden.

Carl-Johan Brahme (CJ)

Skandion Clinic, Uppsala, Sweden.

Isabelle Rydén (I)

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden.

Asgeir S Jakola (AS)

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden.
Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

Einar O Vik-Mo (EO)

Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.

Hanne C Lie (HC)

Department of Behavioural Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.

Lars Asphaug (L)

Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway.

Maziar Hervani (M)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Ingrid Kristensen (I)

Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.

Corina Silvia Rueegg (CS)

Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.

Inge C Olsen (IC)

Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway.

Rolf J Ledal (RJ)

Norwegian Brain Tumor Alliance, Oslo, Norway.

Eskil Degsell (E)

Swedish Brain Tumor Association, Stockholm, Sweden.

Katja Werlenius (K)

Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden.

Malin Blomstrand (M)

Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden.

Petter Brandal (P)

Department of Oncology, Oslo University Hospital, Oslo, Norway.
Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH